Target intelligence / Profile preview

Gastric muscle

Molecular classification
Other
01

Overview

The term "gastric muscle" refers broadly to the smooth muscle tissue found in the wall of the stomach. This tissue is responsible for generating contractions that mix and propel stomach contents during digestion. Gastric smooth muscle function is regulated by multiple cell types including smooth muscle cells, interstitial cells of Cajal (pacemaker cells), and PDGFRα+ fibroblast-like cells, each contributing differently to electrical activity and response to neurotransmitters. The primary molecular targets within gastric muscle are not unique molecules but rather families of receptors—most notably muscarinic acetylcholine receptors (M2 and M3) which mediate cholinergic stimulation leading to contraction, as well as purinergic P2Y1 receptors on associated interstitial cells that modulate inhibitory responses[1][2]. As a whole tissue type rather than a specific molecule or receptor, "gastric muscle" itself is not considered a direct therapeutic target; instead, drugs act on its constituent cellular components. In summary, “gastric muscle” describes an anatomical structure composed mainly of smooth muscle cells regulated by several types of membrane-bound receptors but does not refer to a single defined molecular target suitable for structured drug-target databases.[1][2]

Other names
gastric smooth musclestomach smooth muscle
02

Mechanism of action

Modulation of contraction via activation or inhibition of muscarinic acetylcholine receptors, primarily M2 and M3 subtypes Modulation by purinergic signaling through P2Y1 receptors in associated interstitial cells

03

Biological functions

Contraction and relaxation of the stomach wall (motility)Regulation of gastric emptying and mixing of food with gastric secretionsResponse to neurotransmitters such as acetylcholine via muscarinic receptors
04

Disease associations

Gastrointestinal motility disorders (e.g., gastroparesis, functional dyspepsia)Other (as a tissue involved in various GI diseases)
05

Safety considerations

Non-specific targeting can affect other smooth muscles throughout the body, leading to side effects such as altered gut motility or cardiovascular effects.
06

Interacting drugs

Muscarinic receptor agonists/antagonists (e.g., bethanechol, atropine)

1 more in the full profile.

Beyond the preview

Go deeper on Gastric muscle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric muscle.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call